Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals Inc (ELDN) Covered Calls
As of September 22, 2026, ELDN has 2 covered call opportunities in the coming three months. Return ranges from 81.7 to 83.4% until expiration. Annualized return ranges from 126.3 to 198.7%. The nearest expiration is February 19, 2027. Maximum potential profit is $241.
Read more
Running ELDN covered calls helps you generate consistent income from Eledon Pharmaceuticals Inc's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Eledon Pharmaceuticals Inc involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best ELDN covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if ELDN stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling ELDN covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Eledon Pharmaceuticals Inc covered call is worth writing.
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc.
and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Income-focused investors, long-term ELDN holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling ELDN covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Eledon Pharmaceuticals Inc covered calls come to you, already filtered for the metrics that matter.
Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV percentile82.54% Elevated
- Market cap (M$)235
- 52 weeks high-37.17%
- 52 weeks low114.07%
- Analyst recommendationStrong Buy
1.00 - Target price$9.50
252.50% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-13
- P/E—
- Future P/E—
- EPS (ttm)-0.99
- EPS growth next 5 years-17.33%
As of September 22, 2026
| 2027-02-19 | 150 | 5.00 | 73.01 | 0.25 | 0.30 | 236.00 | 81.66 | 198.71 | -8.65 | +0.31 | 1,118 | 0.05 |
| 2027-05-21 | 241 | 5.00 | 73.01 | 0.30 | 0.90 | 241.00 | 83.39 | 126.30 | -10.38 | +0.46 | 1 | 0.60 |
As of September 22, 2026
Sell covered calls with the data behind you
Find the best ELDN covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.
Start your 14-day free trial→